Spots Global Cancer Trial Database for metastatic urothelial cancer
Every month we try and update this database with for metastatic urothelial cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer | NCT04223856 | Urothelial Canc... | Enfortumab vedo... Pembrolizumab Cisplatin Carboplatin Gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | NCT06225596 | Metastatic Urot... | BT8009 BT8009 BT8009 Pembrolizumab Gemcitabine + c... Avelumab | 18 Years - | BicycleTx Limited | |
| ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer | NCT01963052 | Metastatic Urot... | AGS15E | 18 Years - | Astellas Pharma Inc | |
| A Study of MFA-370 in Patients With Metastatic Urothelial Cancer | NCT05390645 | Metastatic Urot... | MFA-370 | 18 Years - | Ectin Research AB | |
| Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer | NCT02826564 | Metastatic Urot... | pembrolizumab | 18 Years - | University Hospital, Ghent | |
| A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | NCT03679767 | Metastatic Non-... Locally Advance... Metastatic Urot... Unresectable Me... Metastatic Mela... Locally Advance... Metastatic Clea... | Retifanlimab | 18 Years - | Incyte Corporation | |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer | NCT04045613 | Urothelial Carc... | Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 30... Derazantinib 20... | 18 Years - | Basilea Pharmaceutica | |
| Paclitaxel and TAK-228 in Urothelial Carcinoma | NCT03745911 | Metastatic Urot... | Paclitaxel and ... | 18 Years - | Associació per a la Recerca Oncologica, Spain | |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | NCT03288545 | Carcinoma, Tran... Urinary Bladder... Urologic Neopla... Renal Pelvis Ne... Urothelial Canc... Ureteral Neopla... Urethral Neopla... | enfortumab vedo... pembrolizumab cisplatin carboplatin gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Pazopanib and Vinflunine in Urothelial Cancer of the Bladder | NCT01265940 | Advanced Urothe... | Pazopanib as ad... | 18 Years - | Lukas-Krankenhaus GmbH | |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | NCT03547973 | Metastatic Urot... | Sacituzumab Gov... Pembrolizumab Cisplatin Avelumab Zimberelimab Carboplatin Gemcitabine Domvanalimab | 18 Years - | Gilead Sciences | |
| Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer | NCT03451331 | Metastatic Urot... | Nivolumab Gemcitabine Carboplatin Oxaliplatin | 18 Years - | Hoosier Cancer Research Network | |
| A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | NCT02091999 | Metastatic Urot... | enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations | NCT03448718 | Metastatic Urot... | Olaparib | 18 Years - | Hoosier Cancer Research Network | |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer | NCT04045613 | Urothelial Carc... | Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 30... Derazantinib 20... | 18 Years - | Basilea Pharmaceutica | |
| A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer | NCT03785925 | Urinary Bladder... Neoplasm Metast... | Bempegaldesleuk... Nivolumab | 18 Years - | Nektar Therapeutics | |
| A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | NCT03679767 | Metastatic Non-... Locally Advance... Metastatic Urot... Unresectable Me... Metastatic Mela... Locally Advance... Metastatic Clea... | Retifanlimab | 18 Years - | Incyte Corporation | |
| Pazopanib and Vinflunine in Urothelial Cancer of the Bladder | NCT01265940 | Advanced Urothe... | Pazopanib as ad... | 18 Years - | Lukas-Krankenhaus GmbH | |
| A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | NCT02091999 | Metastatic Urot... | enfortumab vedo... | 18 Years - | Astellas Pharma Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
